Nama's AI scorecard currently rates Corcept Therapeutics Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is CORT's P/E ratio?

Corcept Therapeutics trades at a trailing price-to-earnings ratio of 57.3.

When does CORT report earnings?

Corcept Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.20.

What is the CORT price target?

The median analyst price target from 5 analysts is $164.00, with a range of $50.00 – $173.00.

Is CORT Shariah compliant?

Nama's AAOIFI-style screen reads Corcept Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Corcept Therapeutics (CORT)

Healthcare · Biotechnology · NASDAQ

Corcept Therapeutics (CORT) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $7.96B, a trailing price-to-earnings ratio of 57.3 and a free-cash-flow yield of 1.6%. Over the most recent reported fiscal year, revenue grew 12.8% and free cash flow per share fell 31.6%. Nama's AI scorecard rates it Hold, 5.5 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Hold · 5.5/10

The sections balance. As of Nov 7, 2026.

Momentum

Rising · +63.7% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-42.4%

How far the last close sits under the highest price of the past five years.

Market cap	$7.96B
Trailing P/E	57.3
Price / book	11.1
Price / sales	9.5
FCF yield	1.6%
Dividend yield	—
Gross margin	98.3%
Operating margin	0.8%
Net margin	6.6%
Revenue growth (YoY)	+12.8%
Revenue growth (3-yr annual)	+23.7%
EPS growth (YoY)	-33.9%
FCF/share growth (YoY)	-31.6%
Beta	0.4
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

CORT earnings

Next report: Feb 24, 2027 (Q4 2026, EPS estimate $1.20). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$1.01	$0.84	+20.2%	$340.47M
Q2 2026	Jul 29, 2026	$0.36	$0.06	+500.0%	$256.15M
Q1 2026	Apr 30, 2026	-$0.30	-$0.14	-114.3%	$164.90M
Q4 2025	Feb 24, 2026	$0.20	$0.33	-39.4%	$202.12M

CORT analyst price target

Median target $164.00 from 5 analysts, ranging $50.00 – $173.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live CORT data on Nama Insights →

CORT FAQ

Is CORT a buy?: Nama's AI scorecard currently rates Corcept Therapeutics Hold (5.5 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is CORT's P/E ratio?: Corcept Therapeutics trades at a trailing price-to-earnings ratio of 57.3.
When does CORT report earnings?: Corcept Therapeutics's next scheduled report is on Feb 24, 2027. Analysts expect EPS of $1.20.
What is the CORT price target?: The median analyst price target from 5 analysts is $164.00, with a range of $50.00 – $173.00.
Is CORT Shariah compliant?: Nama's AAOIFI-style screen reads Corcept Therapeutics as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.